Acceleron Pharma Inc., of Cambridge, Mass., highlighted the publication of final results from its phase I trial of ACE-083, a locally acting engineered protein therapeutic for the potential treatment of diseases such as facioscapulohumeral dystrophy (FSHD) and Charcot-Marie-Tooth disease.